Novel and Investigational Drugs in Depression

References (98)

1. 1 NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses [DOI]
2. 2 Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors [DOI]
3. 3 Glutamate N-methyl-D-aspartate Receptor Antagonists Rapidly Reverse Behavioral and Synaptic Deficits Caused by Chronic Stress Exposure [DOI]
4. 4 Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder [DOI]
5. 5 An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder [DOI]
6. 6 A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder [DOI]
7. 7 Increased Number of Vasopressin- and Oxytocin-Expressing Neurons in the Paraventricular Nucleus of the Hypothalamus in Depression [DOI]
8. 8 Molecular Cell Biology [DOI]
9. 9 Course of Improvement in Depressive Symptoms to a Single Intravenous Infusion of Ketamine vs Add-on Riluzole: Results from a 4-Week, Double-Blind, Placebo-Controlled Study [DOI]
10. 10 Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats [DOI]
11. 11 Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects [DOI]
12. 12 The cholinergic hypothesis of cognitive aging revisited again: Cholinergic functional compensation [DOI]
13. 13 Daily Oral Ketamine for the Treatment of Depression and Anxiety in Patients Receiving Hospice Care: A 28-Day Open-Label Proof-of-Concept Trial [DOI]
14. 14 Psychotherapeutic Benefits of Opioid Agonist Therapy [DOI]
15. 15 A Randomized, Double-Blind, Placebo-Controlled, 8-Week Study of Vilazodone, a Serotonergic Agent for the Treatment of Major Depressive Disorder [DOI]
16. 16 Persistent β 2 *-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder [DOI]
17. 17 Selective Serotonin Reuptake Inhibitor Discontinuation [DOI]
18. 18 Innovative Drugs to Treat Depression: Did Animal Models Fail to Be Predictive or Did Clinical Trials Fail to Detect Effects? [DOI]
19. 19 Novel glutamatergic drugs for the treatment of mood disorders [DOI]
20. 20 Opiate Treatment in Depression Refractory to Antidepressants and Electroconvulsive Therapy [DOI]
21. 21 A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder [DOI]
22. 22 Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder [DOI]
23. 23 Is There Anything Really Novel on the Antidepressant Horizon? [DOI]
24. 24 POSSIBLE ANTIDEPRESSIVE EFFECTS OF OPIOIDS: ACTION OF BUPRENORPHINE [DOI]
25. 25 The thermolabile variant of MTHFR is associated with depression in the British Women's Heart and Health Study and a meta-analysis [DOI]
26. 26 Methylenetetrahydrofolate reductase variant and schizophrenia/depression [DOI]
27. 27 An Overview of SSR149415, a Selective Nonpeptide Vasopressin V1b Receptor Antagonist for the Treatment of Stress-Related Disorders [DOI]
28. 28 Pharmacokinetic Drug Interactions Involving Vortioxetine (Lu AA21004), a Multimodal Antidepressant [DOI]
29. 29 Varenicline Augmentation in Depressed Smokers [DOI]
30. 30 The Vasopressin V1bReceptor Antagonist SSR149415 in the Treatment of Major Depressive and Generalized Anxiety Disorders [DOI]
31. 31 Novel Therapeutics for Depression:L-methylfolate as a Trimonoamine Modulator and Antidepressant-Augmenting Agent [DOI]
32. 32 Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study [DOI]
33. 33 Vortioxetine: First Global Approval [DOI]
34. 34 The role of folic acid in prevention and treatment of depression: An overview of existing evidence and implications for practice [DOI]
35. 35 A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia [DOI]
36. 36 Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor [DOI]
37. 37 New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder [DOI]
38. 38 An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan [DOI]
39. 39 A review of current evidence for vilazodone in major depressive disorder [DOI]
40. 40 The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder [DOI]
41. 41 Electrophysiological evidence for rapid 5-HT1A autoreceptor inhibition by vilazodone, a 5-HT1A receptor partial agonist and 5-HT reuptake inhibitor [DOI]
42. 42 The MTHFR C677T polymorphism is associated with depressive episodes in patients from Northern Ireland [DOI]
43. 43 Milnacipran: a unique antidepressant? [DOI]
44. 44 Vilazodone in the treatment of major depressive disorder [DOI]
45. 45 Augmenting antidepressant response with folates [DOI]
46. 46 Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output [DOI]
47. 47 The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder [DOI]
48. 48 Mechanism of action of dextromethorphan/quinidine: comparison with ketamine [DOI]
49. 49 Depression drug disappoints [DOI]
50. 50 Einführung in die psychiatrische Klinik : zweiunddreißig Vorlesungen
51. 51 Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010 [DOI]
52. 52 mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists [DOI]
53. 53 Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial [DOI]
54. 54 Opioid receptors: distinct roles in mood disorders [DOI]
55. 55 Stahl's Essential Psychopharmacology [DOI]
56. 56 Allosteric modulators of NR2B‐containing NMDA receptors: molecular mechanisms and therapeutic potential [DOI]
57. 57 Treatment of depression: time to consider folic acid and vitamin B12 [DOI]
58. 58 Methylenetetrahydrofolate Reductase (MTHFR) Genetic Polymorphisms and Psychiatric Disorders: A HuGE Review [DOI]
59. 59 Buprenorphine Treatment of Refractory Depression [DOI]
60. 60 Lurasidone Monotherapy in the Treatment of Bipolar I Depression: A Randomized, Double-Blind, Placebo-Controlled Study [DOI]
61. 61 Plasma Levels of Arginine Vasopressin Elevated in Patients with Major Depression [DOI]
62. 62 Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice [DOI]
63. 63 Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression [DOI]
64. 64 Nicotinic acetylcholine receptors as targets for antidepressants [DOI]
65. 65 l -Methylfolate as Adjunctive Therapy for SSRI-Resistant Major Depression: Results of Two Randomized, Double-Blind, Parallel-Sequential Trials [DOI]
66. 66 Levomilnacipran (F2695), a norepinephrine-preferring SNRI: Profile in vitro and in models of depression and anxiety [DOI]
67. 67 A Randomized Trial of a Low-Trapping Nonselective N-Methyl-D-Aspartate Channel Blocker in Major Depression [DOI]
68. 68 Acetylcholine and Depression* [DOI]
69. 69 Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? [DOI]
70. 70 Varenicline Improves Mood and Cognition During Smoking Abstinence [DOI]
71. 71 A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive Disorder [DOI]
72. 72 Stahl's Essential Psychopharmacology [DOI]
73. 73 Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature [DOI]
74. 74 Maintenance Treatment of Depression in Old Age [DOI]
75. 75 Guidelines for the Management of Cognitive and Behavioral Problems in Dementia [DOI]
76. 76 Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression [DOI]
77. 77 Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? [DOI]
78. 78 Effects of Varenicline on Smoking Cessation in Adults With Stably Treated Current or Past Major Depression [DOI]
79. 79 GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists [DOI]
80. 80 Ketamine as a new treatment for depression: A review of its efficacy and adverse effects [DOI]
81. 81 Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: Evidence for direct 5-HT receptor modulation [DOI]
82. 82 The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats [DOI]
83. 83 Rapid-acting antidepressant strategies: mechanisms of action [DOI]
84. 84 Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder [DOI]
85. 85 Alterations in Arginine Vasopressin Neurons in the Suprachiasmatic Nucleus in Depression [DOI]
86. 86 Involvement of Sigma-1 Receptors in the Antidepressant-like Effects of Dextromethorphan [DOI]
87. 87 A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression [DOI]
88. 88 Mechanism of action of ketamine [DOI]
89. 89 Glutamate system as target for development of novel antidepressants [DOI]
90. 90 Vilazodone: A novel antidepressant [DOI]
91. 91 Levomilnacipran (Fetzima) [DOI]
92. 92 Cognition as a therapeutic target in late-life depression: Potential for nicotinic therapeutics [DOI]
93. 93 The MTHFR C677T polymorphism is associated with depressive episodes in patients from Northern Ireland [DOI]
94. 94 Depression and Bipolar Disorder. Stahl's Essential Psychopharmacology
95. 95 Evidence for the Use of L -Methylfolate Combined With Antidepressants in MDD [DOI]
96. 96 Developments in Psychopharmacology for Major Depressive Disorder [DOI]
97. 97 Agomelatine versus other antidepressive agents for major depression [DOI]
98. 98 [Mechanism of action of ketamine].

Cited by 2

Showing 1 of 2 known citations — external sources report more than can currently be individually listed.

Related research

• Prevalence and Correlates of Major Depressive Disorder among Human Immunodeficiency Virus Infected Adults in Sub-Saharan Africa: A Systematic Review and Meta-analysis — shares topic coverage
• Plant Medicine Healing! Discovering the Roots of Psychedelic-Assisted Therapy in Mental Health — shares topic coverage
• Association of Major Depression with Serum Prolidase Activity and Oxidative Stress — shares topic coverage
• Determining the Impact of Borderline Personality Disorder in the Treatment Outcome of Depression — shares topic coverage
• Escitalopram Usage Pattern in India: A Knowledge, Attitude and Practice Survey among Indian Psychiatrists — shares topic coverage